Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series

Lavinia Spain, Gerard Walls, Christina Messiou, Samra Turajlic, Martin Gore, James Larkin

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background
The efficacy and potential toxicity of rechallenge with combination ipilimumab and nivolumab has not been described. Retreatment of patients with immune checkpoint inhibitors in the setting of prior significant toxicity lacks evidence-based guidance.

Methods
We present the first three, consecutive patients who received re-treatment with combination ipilimumab and nivolumab for metastatic melanoma managed at our institution.

Results
Rechallenge with combination ipilimumab and nivolumab in the setting of prior grade 3 toxicity with initial combination therapy is feasible, and responses are seen. We highlight the fact that grade 3 toxicity is likely to recur, but if so, can be manageable.

Conclusions
Retreatment with ipi + nivo may be considered an option in carefully selected, well-informed patients. More research is required to delineate the benefits and risks with this approach.
Original languageEnglish
Pages (from-to)113-117
JournalCancer immunology, immunotherapy : CII
Volume66
Issue number1
DOIs
Publication statusPublished - 12 Nov 2016

Keywords

  • Advanced melanoma
  • Combination immune checkpoint therapy
  • Immune-related toxicity
  • Ipilimumab
  • Nivolumab

Fingerprint Dive into the research topics of 'Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series'. Together they form a unique fingerprint.

  • Cite this